Evidence map›Paper›PMID 21741349›Full record

ArticleActa tropica2012

Malaria in selected non-Amazonian countries of Latin America.

Myriam Arevalo-Herrera, Martha Lucia Quiñones, Carlos Guerra, Nora Céspedes, Sandra Giron, Martha Ahumada, Juan Gabriel Piñeros, Norma Padilla, Zilka Terrientes, Angel Rosas and 4 more

Open access · greenAbstract read
In one paragraph

Article in Acta tropica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Antibody Responses AgainstFrontiers in cellular and infection microbiology · 2020
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Myriam Arevalo-HerreraCentro de Investigación Científica Caucaseco, Colombia. marevalo@inmuno.org
Martha Lucia Quiñones
Carlos Guerra
Nora Céspedes
Sandra Giron
Martha Ahumada
Juan Gabriel Piñeros
Norma Padilla
Zilka Terrientes
Angel Rosas
Julio Cesar Padilla
Ananias A Escalante
John C Beier
Socrates Herrera
Caucaseco Scientific Research Center · COArizona State University · USInstituto Conmemorativo Gorgas de Estudios de la Salud · PAMinistry of Health and Social Protection · COUniversidad de Antioquia · COUniversidad del Valle · COUniversidad del Valle de Guatemala · GTUniversity of Miami · USUniversity of Oxford · GB

Funding

Vector Biology Research and Integrated Vector Management For Malaria ControlU19AI089702 · NIAID · CAUCASECO SCIENTIFIC RESEARCH CENTER · PI QUINONES, MARTHA · 2010 to 2016
$11.5M
Development of a P. vivax immunization and sporozoite challenge model for humanR01HL086488 · NHLBI · MALARIA VACCINE DEVELOPMENT CENTER · PI HERRERA, SOCRATES · 2008 to 2011
$1.2M
NHLBI NIH HHS R01 HL086488NIAID NIH HHS U19 AI089702
6 · The paper itself

Abstract

Approximately 170 million inhabitants of the American continent live at risk of malaria transmission. Although the continent's contribution to the global malaria burden is small, at least 1-1.2 million malaria cases are reported annually. Sixty percent of the malaria cases occur in Brazil and the other 40% are distributed in 20 other countries of Central and South America. Plasmodium vivax is the predominant species (74.2%) followed by P. falciparum (25.7%) and P. malariae (0.1%), and no less than 10 Anopheles species have been identified as primary or secondary malaria vectors. Rapid deforestation and agricultural practices are directly related to increases in Anopheles species diversity and abundance, as well as in the number of malaria cases. Additionally, climate changes profoundly affect malaria transmission and are responsible for malaria epidemics in some regions of South America. Parasite drug resistance is increasing, but due to bio-geographic barriers there is extraordinary genetic differentiation of parasites with limited dispersion. Although the clinical spectrum ranges from uncomplicated to severe malaria cases, due to the generally low to middle transmission intensity, features such as severe anemia, cerebral malaria and other complications appear to be less frequent than in other endemic regions and asymptomatic infections are a common feature. Although the National Malaria Control Programs (NMCP) of different countries differ in their control activities these are all directed to reduce morbidity and mortality by using strategies like health promotion, vector control and impregnate bed nets among others. Recently, international initiatives such as the Malaria Control Program in Andean-country Border Regions (PAMAFRO) (implemented by the Andean Organism for Health (ORAS) and sponsored by The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)) and The Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA) (sponsored by the Pan American Health Organization/World Health Organization (PAHO/WHO) and several other partners), have made great investments for malaria control in the region. We describe here the current status of malaria in a non-Amazonian region comprising several countries of South and Central America participating in the Centro Latino Americano de Investigación en Malaria (CLAIM), an International Center of Excellence for Malaria Research (ICEMR) sponsored by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

Indexed as

AnimalsAnophelesAntimalarialsDisease EradicationDrug ResistanceHumansInsecticidesInsect VectorsInternational CooperationLatin AmericaMalariaMosquito ControlNational Health ProgramsPlasmodiumProgram EvaluationAntimalarialsInsecticides

Identifiers

PMID21741349
PMCPMC3237935
OpenAlexW2051805785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.